1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
January 2024 in “Wiadomości Lekarskie” DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.
March 2026 in “Cosmoderma” Venusia CeraPlus cream and lotion effectively reduce eczema severity and improve skin moisture.
1 citations
,
January 2023 in “Frontiers in veterinary science” Activating autophagy in dogs with certain diseases improves their skin and hair.
January 2026 in “International Society of Hair Restoration Surgery” Tattoo machine-assisted drug delivery may improve hair growth in androgenetic alopecia.
April 2014 in “Significance” Unconventional home remedies can sometimes show surprising results.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
8 citations
,
October 2024 in “Cochrane Database of Systematic Reviews” Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.
January 2024 in “Wiadomości Lekarskie” Point of Care in radiology speeds up diagnosis and treatment by performing tests where the patient is.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
1 citations
,
January 2010 in “Via Medica Journals” Thyroid ultrasounds are essential but need skill and experience for accurate results.
17 citations
,
September 2022 in “Biomaterials Research” The film-trigger applicator improves microneedle skin delivery and drug efficiency using simple finger force.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
June 2023 in “British Journal of Dermatology” The prototype for analyzing skin aging works technically and clinically.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
4 citations
,
June 2024 in “The Kaohsiung Journal of Medical Sciences” Atg5 can promote tumors when autophagy is deficient but suppresses them under normal conditions.
March 2026 in “Frontiers in Pharmacology” Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
15 citations
,
January 2019 in “Journal of the Formosan Medical Association” Adalimumab helped control a child's severe eye disease when other treatments failed.
April 2026 in “Benha Medical Journal” 97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
11 citations
,
January 2020 in “Journal of Drugs in Dermatology” Intralesional triamcinolone acetonide is effective and safe for treating early to mid-stage traction alopecia.